10 September 2026
Source: American Association for Cancer Research (AACR).
This is particularly important from a quality-of-life perspective.
Researchers investigated whether giving immunochemotherapy before surgery could shrink tumours sufficiently to allow surgeons to perform less extensive operations.
The study involved 52 people with locally advanced HPV-negative head and neck squamous cell carcinoma.
Patients received three cycles of immunochemotherapy before surgery.
Those whose tumours shrank by at least 50% were offered reduced-volume surgery, designed to remove the remaining cancer while preserving surrounding structures and organs.
The research reported encouraging disease-free survival and organ preservation outcomes.
Why this matters: Treatment success is not simply about surviving cancer. It is also about preserving speech, swallowing, appearance and quality of life. This research explores whether immunotherapy can help achieve both objectives.
